Microwave Ablation vs Uterine Artery Embolization for Adenomyosis
What this 2026 randomized pilot study means and why it reinforces the ESSI uterus-preserving model
For symptomatic adenomyosis, the first randomized controlled pilot study comparing microwave ablation (MWA) with uterine artery embolization (UAE) found that both approaches improved symptoms, but microwave therapy delivered clearly better recovery: shorter hospitalization, faster return to daily activities, and fewer days of postoperative pain medication.
For ESSI, that matters because adenomyosis care should not be judged only by whether symptoms move in the right direction, but by how effectively the treatment improves the patient’s life while preserving options.
ESSI Takeaways
-
Both MWA and UAE improved adenomyosis symptoms in this small trial, but MWA patients recovered much faster.
-
MWA patients had a median hospitalization of 0 days versus 3 days for UAE, and returned to daily activities in 3 days versus 14 days.
-
The trial did not prove a primary-outcome superiority of MWA at 6 months, so the recovery advantage is the clearest differentiator.
-
The paper does not prove ovarian damage from UAE in this cohort.
-
Fertility and ovarian reserve concerns around UAE come from broader literature and deserve careful counseling, not overstatement.
What the paper actually studied
The study enrolled 20 premenopausal women with symptomatic adenomyosis at Danderyd Hospital in Sweden from 2020 to 2023. Patients were randomized 1:1 to MWA or UAE, with analysis ultimately including eight MWA patients and seven UAE patients.
The primary endpoint was symptom severity score (SSS) at 6 months using the UFS-QoL questionnaire. Secondary endpoints included quality of life, menstrual bleeding, dysmenorrhea, uterine volume, laboratory markers including AMH, hospitalization, pain medication use, and acceptability.
The headline result: both worked, but MWA recovered better
The primary outcome did not significantly differ between groups. Symptom severity improved in both arms: the MWA group fell from 69 to 44, while the UAE group fell from 88 to 47. Quality of life also improved in both groups. Dysmenorrhea dropped from a median of 6 to 1 after MWA and from 9 to 4 after UAE.
Where the separation became clinically meaningful was recovery. MWA patients had significantly shorter hospitalization—median 0 days versus 3 days for UAE—and a significantly quicker return to daily activities: 3 days versus 14 days. They also used fewer days of postoperative pain medication, 3 versus 10 days.
What the MRI images show
The paper includes illustrative sagittal MRI examples. They are not outcome proofs by themselves, but they are visually compelling examples of post-treatment change. Figure 1 shows the MWA example from baseline to 6 months. Figure 2 shows the UAE example over the same interval.
The data snapshot that matters most
Below is a clear visual representation of how both treatments performed six months post-procedure. This chart tracks the percentage improvement across four critical categories: Symptom Severity Score (SSS), Health-Related Quality of Life (HR-QoL), menstrual bleeding (PBAC), and Dysmenorrhea (pelvic pain and cramping).
For ESSI readers, the key takeaway is visually apparent: both interventions provide robust relief. While UAE showed slightly higher percentage improvements in overall symptom severity and quality of life scores in this specific cohort, MWA delivered a striking advantage in reducing dysmenorrhea (over an 80% improvement). The practical message remains clear—UAE did not fail, but MWA achieved highly meaningful, targeted symptom relief (especially for debilitating pain) while offering a significantly faster and easier recovery profile.
Why this paper supports the ESSI philosophy
At ESSI, we have argued that adenomyosis deserves more than a reflexive choice between hormonal suppression and hysterectomy. This study strengthens that middle ground. It shows that microwave therapy can produce real symptom improvement with a very attractive recovery profile. That is exactly why MWA fits the ESSI uterus-preserving model, particularly in patients who want rapid recovery, symptom relief, and preservation of reproductive potential.
It also fits the ESSI reality that adenomyosis frequently coexists with endometriosis. In the real world, many patients need more than one modality: excision for extrauterine disease and a uterus-preserving strategy for disease embedded within the uterine muscle. MWA gives us a way to address that uterine component without defaulting to hysterectomy.
A careful word on embolization and the ovaries
This is where precision matters. The pilot trial itself did not demonstrate a statistically significant ovarian-reserve disadvantage for UAE at 6 months; the AMH comparison between groups was not significant. So it would be inaccurate to claim that this paper proves UAE damages the ovaries.
That said, fertility-conscious counseling around UAE is still important. Older randomized and review literature has reported concern about ovarian reserve after UAE, especially in older premenopausal women, while other meta-analytic work has found no clear overall AMH or FSH effect but emphasized low-quality evidence and the need for caution. In other words: the ovarian-risk question is not settled enough for sweeping claims, but it is real enough that UAE should be discussed carefully in patients prioritizing fertility or ovarian reserve.
At ESSI, that is one reason MWA is so appealing. Prior PMWA literature has reported effective symptom reduction without demonstrating a significant adverse effect on ovarian reserve, and the present randomized pilot adds a practical advantage: faster recovery.
How rare is this in the United States?
MWA for adenomyosis remains uncommon in U.S. practice. In the public-facing web material reviewed for this post, ESSI stands out as one of the very few U.S. centers openly advertising and championing microwave therapy for adenomyosis. I am not comfortable claiming an absolute national monopoly without a comprehensive market audit, but it is fair to say that this remains a rare offering in the United States and a defining part of ESSI’s modern adenomyosis strategy.
The ESSI bottom line
This paper does not say UAE never works. It clearly can. What it does say is that microwave ablation deserves to be taken seriously as a front-line uterus-preserving option for appropriately selected adenomyosis patients.
In this randomized pilot, both techniques improved symptoms, but MWA delivered the kind of postoperative experience patients actually feel: shorter hospitalization, faster return to life, and less medication burden. That is why ESSI believes microwave therapy belongs in the U.S. conversation now. For the right patient, it offers a modern answer to an old problem: treat the disease, preserve the uterus, and minimize the price the patient has to pay to get better.
References
-
Jonsdottir G, Lantz E, Beermann M, Paschou M, Kallner HK, Hasselrot K. Symptom improvement in adenomyosis patients after ultrasound guided microwave ablation or uterine artery embolization, A randomized controlled pilot study. PLoS One. 2026;21(3):e0343949. doi:10.1371/journal.pone.0343949.
-
Yang Y, et al. Ultrasound-guided percutaneous microwave ablation for adenomyosis: efficacy of treatment and effect on ovarian function. Scientific Reports. 2015;5:10034.
-
Hehenkamp WJK, et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Human Reproduction. 2007;22(7):1996-2005.
-
El Shamy T, et al. The impact of uterine artery embolization on ovarian reserve: a systematic review and meta-analysis. Acta Obstetricia et Gynecologica Scandinavica. 2020;99:16-23.
-
Dason ES, Maxim M, Sanders A, et al. Guideline No. 437: Diagnosis and Management of Adenomyosis. Journal of Obstetrics and Gynaecology Canada. 2023.
Image source note: The paper and extracted figure/table images used here are from an open-access PLOS One article distributed under the Creative Commons Attribution License.
